Citations

Showing 10 of 108083 citations.

Benign Breast Disease, NSAIDs, and Postmenopausal Breast Cancer Risk in the CPS-II Cohort
Sherman, Mark E. , Vierkant, Robert A. , Masters, Matthew , Radisky, Derek C. , Winham, Stacey J. , Degnim, Amy C. , Vachon, Celine M. , Patel, Alpa V. , Teras, Lauren R. , Winham, Stacey J , Degnim, Amy C , Vierkant, Robert A , Teras, Lauren R , Sherman, Mark E , Radisky, Derek C , Vachon, Celine M.

Mayo Clinic

Cancer Prevention Research | January 3, 2023 | Volume: 16 | Issue: 3 | Pages: 175-184

10.1158/1940-6207.capr-22-0403 | PMID 36596665 Get It

Abstract Nonsteroidal anti-inflammatory agents (NSAID) are associated with modest inconsistent reductions in breast cancer risk in population-based cohorts, whereas two focused studies of patients with benign breast disease (BBD) have found lower risk with NSAID use. Given that BBD includes fibroinflammatory lesions linked to elevated breast cancer risk, we assessed whether NSAID use was associated with lower breast cancer risk among patients with BBD. Participants were postmenopausal women in the Cancer Prevention Study-II (CPS-II), a prospective study of cancer incidence and mortality, who completed follow-up surveys in 1997 with follow-up through June 30, 2015. History of BBD, NSAID use, and covariate data were updated biennially. This analysis included 23,615 patients with BBD and 36,751 patients with non-BBD, including 3,896 incident breast cancers over an average of 12.72 years of follow-up among participants. NSAID use, overall and by formulation, recency, duration, and pills per month was analyzed versus breast cancer risk overall and by BBD status using multivariable-adjusted Cox models; BBD status and NSAID use were modeled as time-dependent exposures. Patients with BBD who reported using NSAIDs experienced lower breast cancer risk (HR, 0.87; 95% CI, 0.78–0.97), with similar effects for estrogen receptor (ER)-positive breast cancers [HR, 0.85; 95% confidence interval (CI), 0.74–0.97] and ER-negative breast cancers (HR, 0.87; 95% CI, 0.59–1.29); among women without BBD, NSAID use was unrelated to risk (HR, 1.02; 95% CI, 0.92–1.13; Pinteraction = 0.04). Associations stratified by age, obesity, menopausal hormone use, and cardiovascular disease were similar. Among patients with BBD, NSAID use appears linked to lower breast cancer risk. Further studies to assess the value of NSAID use among patients with BBD are warranted. Prevention Relevance: We examined whether NSAID use, a modifiable exposure, is associated with breast cancer risk in postmenopausal women from the Cancer Prevention Study-II with self-reported benign breast disease, an often inflammatory condition associated with higher rates of breast cancer.
Underprepared: influences of U.S. medical students’ self-assessed confidence in immigrant and refugee health care
Stryker, Shanna D. , Conway, Katharine , Kaeppler, Caitlin , Porada, Kelsey , Tam, Reena P. , Holmberg, Peter J., Schubert, Charles J., group, and Medical Student Global Health study, group, and Medical Student Global Health study

Mayo Clinic

Medical Education Online | January 3, 2023 | Volume: 28 | Issue: 1 | Pages: No page available

10.1080/10872981.2022.2161117 | PMID 36594616 Get It

Views of Adolescents and Young Adults with Cancer and Their Oncologists Toward Patients' Participation in Genomic Research
Gutierrez, Amanda M. , Robinson, Jill O. , Raesz-Martinez, Robin, Canfield, Isabel , Majumder, Mary A. , Scollon, Sarah , Desrosiers, Lauren , Hsu, Rebecca , Allen‐Rhoades, Wendy , Parsons, D. Williams , Malek, Janet , Hsu, Rebecca L , Parsons, D Williams , Allen-Rhoades, Wendy A , Scollon, Sarah R , Desrosiers-Battu, Lauren R , Plon, Sharon E. , McGuire, Amy L

Mayo Clinic

Journal of Adolescent and Young Adult Oncology | January 3, 2023 | Volume: 12 | Issue: 5 | Pages: 773-781

10.1089/jayao.2022.0066 | PMID 36595372 Get It

Tissue Eosinophilia is Superior to an Analysis by Polyp Status for the Chronic Rhinosinusitis Transcriptome: An RNA Study
Brar, Tripti , McCabe, Chantal E. , Miglani, Amar , Marino, Michael J. , Lal, Devyani , McCabe, Chantal, Marino, Michael J , Lal, Devyani

Mayo Clinic

The Laryngoscope | January 3, 2023 | Volume: 133 | Issue: 10 | Pages: 2480-2489

10.1002/lary.30544 | PMID 36594502 Get It

ObjectiveRNA sequencing (transcriptomics) is used to study biological pathways. However, the yield of data depends on comparing well‐characterized cohorts. We compared tissue eosinophilia versus nasal polyp (NP) status as the metric to characterize transcriptomic mechanisms at play in eosinophilic and non‐eosinophilic chronic rhinosinusitis (CRS) versus controls.MethodsRNA sequencing was conducted on sinonasal tissue samples of CRS and controls. Analyses were conducted based on polyp status [with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP)] as well as tissue eosinophil levels per high power field (eos/hpf)[non‐eosinophilic (<10 eos/hpf, neCRS) or eosinophilic (≥10 eos/hpf, eCRS)]. The yield of differentially expressed genes (DEGs) and biological pathways through Ingenuity Pathway Analysis (IPA) were compared.ResultsCRS tissue differed from controls by 736 statistically significant DEGs. Both NP status and tissue eosinophilia were effective in differentiating CRS from controls and into two distinct subgroups. Statistically significant DEGs identified when comparing CRS by NP status were 60, whereas 110 DEGs were identified using eosinophil cutoff ≥10 and <10 eos/hpf. Additionally, heatmaps showed greater homogeneity within each CRS subgroup when analyzed by tissue eosinophilia versus NP status. On IPA, the IL‐17 signaling pathway was significantly different only by tissue eosinophilia status, not NP status, being higher in CRS <10 eos/hpf.ConclusionTissue eosinophilia is superior to an analysis by NP status for the study of CRS transcriptome by RNA sequencing in identifying DEGs. Classification of CRS samples by eosinophil counts agnostic of NP status may offer advantageous insights into CRS pathogenetic mechanisms.Level of Evidence3 Laryngoscope, 133:2480–2489, 2023
ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids
Shah, Shalini , Schwenk, Eric S. , Sondekoppam, Rakesh V. , Clarke, Hance , Zakowski, Mark , Rzasa-Lynn, Rachel S, Yeung, Brent , Nicholson, Kate, Schwartz, Gary , Hooten, W. Michael , Wallace, Mark S. , Viscusi, Eugene R. , Narouze, Samer , Schwenk, Eric S , Shah, Shalini , Sondekoppam, Rakesh V , Lynn, Rachael Rzasa , Narouze, Samer

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 3, 2023 | Volume: 48 | Issue: 3 | Pages: 97-117

10.1136/rapm-2022-104013 | PMID 36596580 Get It

Background The past two decades have seen an increase in cannabis use due to both regulatory changes and an interest in potential therapeutic effects of the substance, yet many aspects of the substance and their health implications remain controversial or unclear. Methods In November 2020, the American Society of Regional Anesthesia and Pain Medicine charged the Cannabis Working Group to develop guidelines for the perioperative use of cannabis. The Perioperative Use of Cannabis and Cannabinoids Guidelines Committee was charged with drafting responses to the nine key questions using a modified Delphi method with the overall goal of producing a document focused on the safe management of surgical patients using cannabinoids. A consensus recommendation required ≥75% agreement. Results Nine questions were selected, with 100% consensus achieved on third-round voting. Topics addressed included perioperative screening, postponement of elective surgery, concomitant use of opioid and cannabis perioperatively, implications for parturients, adjustment in anesthetic and analgesics intraoperatively, postoperative monitoring, cannabis use disorder, and postoperative concerns. Surgical patients using cannabinoids are at potential increased risk for negative perioperative outcomes. Conclusions Specific clinical recommendations for perioperative management of cannabis and cannabinoids were successfully created.
Guidelines should consider clinicians’ time needed to treat
Johansson, Minna , Guyatt, Gordon , Montori, Víctor M.

Mayo Clinic

BMJ | January 3, 2023 | Volume: 380 | Issue: No issue available | Pages: e072953

10.1136/bmj-2022-072953 | PMID 36596571 Get It

Time course scRNAseq analysis on host mucosal immune responses to influenza virus infection during aging
Wu, Yue , Fain, Cori E. , Johnson, Aaron J. , Sun, Jie , Tang, Jinyi , Gao, Xiaochen , Li, Chaofan , Zhu, Bibo , Zhang, Ruixuan , Ayasoufi, Katayoun , Johnson, Aaron J. , Dong, Haidong , Sun, Jie

Mayo Clinic

The Journal of Immunology | January 3, 2023 | Volume: 208 | Issue: Supplement_1 | Pages: 114.20-114.20

10.4049/jimmunol.208.supp.114.20 Get It

Abstract Aging has been shown to be one of the major risk factors for host morbidity and mortality following infections with respiratory viruses including influenza virus and SARS-CoV-2. The unique immune properties of the aged hosts not only influence pathogen clearance and tissue damage responses, but also modulate the pathogenesis of the long-term sequalae post acute viral clearance. Currently, the dynamics and features of mucosal immune responses following acute respiratory viral infections in the aged hosts remain to be fully elucidated. Here, we characterized the lung cellular and molecular profiles following influenza virus infection in young (~3-month-old) or aged (~24-month-old) mice with a chronological manner from acute to chronic phase. Using DNA-oligo-conjugated CD45 antibody and i.v. labeling, we were able to distinguish the unique responses of circulating vs lung-resident immune cells to influenza virus infection during aging. These responses were further validated by spectral flow cytometry analysis of the lung innate and adaptive immune cells. Further data analysis and integration are warranted for this unique large data set detailing the single cell molecular profiles of mucosal responses to influenza virus infection comparing young and aged hosts.
Multi-modal immune profiling of mucinous ovarian carcinoma: analysis from the Ovarian Tumor Tissue Analysis/Multidisciplinary Ovarian Cancer Outcomes Group consortia
Meagher, Nicola S. , Hamilton, Phineas T. , Anglesio, Michael S. , Konecny, Gottfried E. , Schildkraut, Joellen M. , Talhouk, Aline , Initiative, Australian Pancreatic Genome, Pearce, Celeste Leigh , Pike, Malcolm C. , Goode, Ellen L. , Anglesio, Michael S , Harris, Holly R. , Initiative, Australian Pancreatic Genome, Friedländer, Michael , Köbel, Martin , Doherty, Jennifer A. , Nelson, Brad H. , DeFazio, Anna , Ramus, Susan J.

Mayo Clinic

The Journal of Immunology | January 3, 2023 | Volume: 208 | Issue: Supplement_1 | Pages: 179.04-179.04

10.4049/jimmunol.208.supp.179.04 Get It

Abstract Mucinous ovarian carcinoma (MOC) is a rare histotype of ovarian cancer. Women with advanced disease (FIGO stage III/IV) have very poor outcomes, with 5-year survival of &lt;20%. Little is known about the anti-tumor immune response in MOC, limiting potential immunotherapeutic options for patients. Immune data from 3 platforms were analysed. A NanoString mRNA expression panel with 39 immune-related genes (n=60 MOC, n=4198 other ovarian histotypes), a NanoString mRNA plexset with PD-1, PD-L1 (n=241 MOC, n=115 upper and lower gastrointestinal (GI) cancers), and 2 multicolor immunofluorescence (mcIF) panels (n=121 MOC) for CD68, PD-L1, PD-1, CD8 and FOXP3. Data overlapped all platforms for 22 MOC. Immune marker expression by ovarian cancer histotype was measured. Uni- and multivariable Cox Proportional Hazards assessed overall survival (OS) within MOC. Hierarchical clustering looked for subgroups of patients based on co-expression of immune genes. Compared to more common high-grade serous ovarian cancer (HGSC) and GI cancers, MOC were less immunologically active. High IGHM expression was associated with poorer OS (HR 1.31 (95% CI 1.02–1.69), p=0.033). High tumor densities of FOXP3 and PD-1 positive cells conferred poorer OS in a model with age, stage and site; however, these and PD-L1 and CD68 were associated with grade. The 39 gene NanoString and mcIF datasets revealed 4 clusters, roughly translating to immune cold, moderate and hot (groups 3,4). mcIF analysis revealed a subset with PD-L1 expression in the absence of T-regulatory cell infiltrates. This study provides novel insights into the MOC immune landscape. Despite relatively low immune activity overall, immunotherapy could be explored for a subset of patients with MOC. Supported by NSW Ministry of Health and UNSW Sydney, through the NSW Health PhD Scholarship Program 2017-2022; Translational Cancer Research Network top-up scholarship 2021
Combination of αPD-1 and extended half-life IL-2 is effective against the GL261 glioma and uniquely reverses GBM-associated immunosuppression
Tritz, Zachariah P. , Malo, Courtney S. , Zastrow, Alexi, Wolf, Delaney, Khadka, Roman H., Fain, Cori E. , Chen, Maggie , Yokanovich, Lila T. , Hansen, Michael, Wang, Chensu , Johnson, Aaron J. , Ayasoufi, Katayoun , Himes, Benjamin , Zastrow, Alexi, Wolf, Delaney M. , Goddery, Emma N. , Jin, Fang , Moynihan, Kelly D , Irvine, Darrell J , Wittrup, K Dane , Parney, Ian F. , Johnson, Aaron J.

Mayo Clinic

The Journal of Immunology | January 3, 2023 | Volume: 208 | Issue: Supplement_1 | Pages: 122.09-122.09

10.4049/jimmunol.208.supp.122.09 Get It

Abstract Glioblastoma multiforme (GBM) is a deadly CNS malignancy with an average survival of ~12–18 months post diagnosis. The unique immune environment of the brain and the immunosuppressive features of GBM complicate the use of immunotherapies against these tumors. We aimed to promote the efficacy of αPD-1 against the GL261 murine model of GBM by supplementing this therapy with an engineered IL-2 cytokine. IL-2 therapy has been used clinically for metastatic melanoma and renal cancer, but its short half-life in circulation necessitated high doses to keep the drug concentration sufficiently high. Fusing IL-2 to the mouse serum albumin molecule (MSA-IL-2), extends the cytokine’s half-life. Neither αPD-1 nor MSA-IL-2 are effective monotherapies for GL261 tumors, but the combination provides durable tumor clearance and prevents subsequent rechallenge. Most strikingly, this combination therapy cleared established GL261 tumors even in mice incapable of MHC class I restricted antigen presentation. Instead, therapeutic efficacy was abrogated by the depletion of CD4 T cells. Our combination therapy also reversed multiple key features of GBM-associated peripheral immune suppression, including depressed CD4 T cell counts and dampened MHC class II expression. Our combination therapy’s ability to overcome these immune derangements associated with glioma growth and to function independent of MHC class I restricted antigen presentation enhance the appeal of this therapy for future translational adaptation. This work was supported by the National Institutes of Health (R01 NS103212) and the Mayo Clinic-Koch Institute Cancer Solutions Team Grant
The SARS-CoV-2 encoded ORF8 protein Stimulates Human Monocytes to Produce Pro-Inflammatory Cytokines
Ruan, Gordon , Wu, Xiaosheng , Nowakowski, Kevin E., Abeykoon, Jithma P. , Tang, Xingyi , Yu, Yue , Witter, Taylor L. , Taupin, Vanessa, Ansell, Stephen M. , Schellenberg, Matthew J. , Manske, Michelle K. , Paludo, Jonas , Badley, Andrew D. , Witzig, Thomas E.

Mayo Clinic

The Journal of Immunology | January 3, 2023 | Volume: 208 | Issue: Supplement_1 | Pages: 125.07-125.07

10.4049/jimmunol.208.supp.125.07 Get It

Abstract Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can result in a cytokine storm that is associated with poor outcomes in patients. The activation of a NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome following SARS-CoV-2 infection has been shown to play a major role in inflammatory immune responses. In this study, we show that open reading frame 8 (ORF8) protein is abundantly secreted as a glycoprotein in vitro. The glycosylated ORF8 stimulates human CD14+/CD16+ monocytes to cause upregulation of proinflammatory cytokine production and cell surface marker expression within 24 hours. The data suggests that stimulation of human monocytes by ORF8 is not receptor mediated. Rather, ORF8 is likely phagocytosed by human monocytes. ORF8 then stimulates the monocytes by independently binding to the NACHT and LRR domains of the NLRP3 protein. Pharmacologic inhibition of NLRP3 significantly diminished the production of pro-inflammatory cytokines from ORF8-stimulated human monocytes. Finally, this study shows that the ORF8 protein is also secreted in patients with newly diagnosed coronavirus disease 2019 (COVID-19). Levels of ORF8 in the blood of patients diagnosed with COVID-19 correlated with disease mortality and trajectory of disease. ORF8 stimulation of monocytes causes pro-inflammatory cytokine production that leads to the development of severe COVID-19.